Irinotecan as maintenance therapy in high-risk hepatoblastoma

Pediatric Blood and Cancer

Volumn 54, Issue 5, 2010, Pages 761-763

  Qayed, Muna ^a   Powell, Christie ^a   Morgan, Elaine R ^b   Haugen, Maureen ^b   Katzenstein, Howard M ^a  

^a CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Hepatoblastoma; Irinotecan; Maintenance

Indexed keywords

AMIFOSTINE; CARBOPLATIN; CEFIXIME; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; IRINOTECAN; TACROLIMUS; VINCRISTINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CASE REPORT; CHILD; CLINICAL TRIAL; DISEASE FREE INTERVAL; DRUG DOSE INCREASE; DRUG SUBSTITUTION; FEMALE; GRAPE JUICE; HEPATOBLASTOMA; HIGH RISK POPULATION; HUMAN; LIVER GRAFT REJECTION; LIVER RESECTION; LIVER TRANSPLANTATION; LUNG METASTASIS; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT DURATION; TUMOR VOLUME; DISEASE FREE SURVIVAL; INFANT; LIVER TUMOR;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; HEPATOBLASTOMA; HUMANS; INFANT; LIVER NEOPLASMS;

EID: 77950463345     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22408     Document Type: Article

References (17)

1. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000;18:2665-2675.
2. Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successful approach - Results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 2000;18:3819-3828.
3. Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: A Pediatric Oncology Group phase II study. J Clin Oncol 2002;20:3438-3444.
4. Malogolowkin MH, Katzenstein HM, Krailo M, et al. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. J Clin Oncol 2008;26:2379-2383.
5. Wagner LM, Perentesis JP, Reid JM, et al. Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children's Oncology Group Phase I Consortium Study. J Clin Oncol 2009;27:523 (Abstract 10017).
6. Katzenstein HM, Rigsby C, Shaw PH, et al. Novel therapeutic approaches in the treatment of children with hepatoblastoma. J Pediatr Hematol Oncol 2002;24:751-755. (Pubitemid 35448742)
7. Gupta A, Yang D, Vethanayagam RR, et al. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse the resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 2006;58:374-383. (Pubitemid 43800742)
8. Stewart CF, Leggas M, Schuetz JD, et al. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 2004;64:7491-7499. (Pubitemid 39372093)
9. Houghton PJ, Cheshire PJ, Hallman JDII, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
10. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-1824.
11. Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: A Pediatric Oncology Group Study. Clin Cancer Res 2001;7:32-37. (Pubitemid 32110202)
12. Bisogno G, Riccardi R, Ruggiero A, et al. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 2006;106:703-707. (Pubitemid 43157635)
13. Bomgaars LR, Bernstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 2007;25:4622-4627. (Pubitemid 350035322)
14. Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized phase II window study of two schedules of inirotecan (CPT-11) and vincristine (VCR) in rhabdomyosarcoma (RMS) at first relapse/disease progression. J Clin Oncol 2008;26:542 (Abstract 10013).
15. Wagner LM, Villablanca JG, Stewart CF, et al. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: A new approach to neuroblastoma therapy consortium study. J Clin Oncol 2009;27:1290-1296.
16. Furman WL, Crews KR, Billups C, et al. Cefixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 2006;24:563-570. (Pubitemid 46630418)
17. Wagner LM, Crews KR, Stewart CF, et al. Reducing irinotecanassociated diarrhea in children. Pediatr Blood Cancer 2008;50: 201-207.